{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T22:44:58Z","timestamp":1720737898477},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T00:00:00Z","timestamp":1460592000000},"content-version":"vor","delay-in-days":834,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.ihj.2013.12.049","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T18:19:32Z","timestamp":1390328372000},"page":"S113-S119","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Pharmacotherapy to reduce arrhythmic mortality"],"prefix":"10.1016","volume":"66","author":[{"given":"Amit","family":"Vora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samhita","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2013.12.049_bib1","first-page":"282","article-title":"Geographical variations in post myocardial infarction mortality and their impact on risk selection","volume":"36","author":"Naslafkih","year":"2004","journal-title":"J Insur Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1161\/CIRCOUTCOMES.110.957803","article-title":"Trends in mortality of acute myocardial infarction after discharge from the hospital; for the myocardial infarction data acquisition system (MIDAS14) study group","volume":"3","author":"Kostis","year":"2010","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.ihj.2013.12.049_bib3","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results","volume":"247","year":"1982","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2013.12.049_bib4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199808203390801","article-title":"Effect of beta blockade on mortality among high risk and low risk patients after myocardial infarction","volume":"339","author":"Gottlieb","year":"1998","journal-title":"NEJM"},{"key":"10.1016\/j.ihj.2013.12.049_bib5","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"Beta blockade after myocardial infarction: systemic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ihj.2013.12.049_bib6","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2004.09.076","article-title":"Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the carvedilol post-infarct survival control in left ventricular dysfunction (CAPRICORN) trial","volume":"45","author":"McMurray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.049_bib8","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199207233270403","article-title":"Effect of antiarrhythmic agent moricizine on survival after myocardial infarction","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003495-199754020-00003","article-title":"Anti-arrhythmic therapies for prevention of sudden cardiac death","volume":"54","author":"Mclister","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ihj.2013.12.049_bib11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(82)92225-5","article-title":"Controlled trial of sotalol for 1 year after myocardial infarction","volume":"1","author":"Julian","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","article-title":"Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with Oral d-Sotalol","volume":"348","author":"Waldo","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib13","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199906173402402","article-title":"Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group","volume":"340","author":"Pacifico","year":"1999","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib14","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/0735-1097(90)90324-I","article-title":"Effect of anti-arrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)","volume":"16","author":"Burkart","year":"1990","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.049_bib15","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/0735-1097(92)90357-S","article-title":"Effect of amiodarone on mortality after myocardial infarction: a double blind, placebo-controlled, pilot study","volume":"20","author":"Ceremuzynski","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.049_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(96)08171-8","article-title":"Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations. CAMIAT","volume":"349","author":"Cairns","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(96)09145-3","article-title":"Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. EMIAT","volume":"349","author":"Julian","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/eurheartj\/ehp100","article-title":"Amiodarone for the prevention of sudden cardiac death: a meta analysis of randomised control trials","volume":"30","author":"Piccini","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2013.12.049_bib19","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of ACE inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandopril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"Kober","year":"1995","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/18.1.41","article-title":"Effect of Ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"18","author":"Cleland","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2013.12.049_bib21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of ACE inhibitor on sudden cardiac death in patients following acute myocardial infarction: a meta analysis of RCTs","volume":"33","author":"Domanski","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.049_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor ramipril on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0735-1097(03)00498-4","article-title":"Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Anti-arrhythmics versus Implantable Defibrillators (AVID) trial","volume":"42","author":"Mitchell","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.049_bib24","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jacc.2005.09.053","article-title":"Reduction in ventricular tachyarrhythmias with statins in the Multicentre Automatic Defibrillator Implantation Trial (MADIT II)","volume":"47","author":"Vyas","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.049_bib25","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.amjcard.2007.07.015","article-title":"Meta-analysis of effect of statin treatment on risk of sudden death","volume":"100","author":"Levantesi","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2013.12.049_bib26","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patietns with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/11536690-000000000-00000","article-title":"Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischaemic effect?","volume":"10","author":"Beri","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ihj.2013.12.049_bib28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"NEJM"},{"key":"10.1016\/j.ihj.2013.12.049_bib29","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.049_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(94)91895-3","article-title":"GESICA. A randomised trial of low dose amiodarone in severe congestive heart failure","volume":"344","author":"Doval","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0197-2456(92)90036-Y","article-title":"Congestive heart failure: survival trial of antiarrhythmic therapy (CHF STAT). The CHF STAT Investigators","volume":"13","author":"Singh","year":"1992","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ihj.2013.12.049_bib32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCULATIONAHA.106.687103","article-title":"Prediction of mode of death in heart failure: the Seattle Heart Failure Model","volume":"116","author":"Mozaffarian","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.049_bib33","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"Effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"A randomised trial of beta blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib35","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib36","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Carvedilol Prospective Randomised Cumulative Survival Study (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.049_bib37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2261-13-52","article-title":"Beta blockers for the prevention of sudden cardiac death in heart failure patients: a meta analysis of randomized controlled trials","volume":"13","author":"Al-Gobari","year":"2013","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ihj.2013.12.049_bib38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"NEJM"},{"key":"10.1016\/j.ihj.2013.12.049_bib39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions the SOLVD investigators","volume":"327","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib40","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","article-title":"Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure","volume":"273","author":"Garg","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2013.12.049_bib41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib42","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial \u2013 the Losartan Heart Failure Survival Study, ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib43","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomised trial of angiotensin receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib44","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effect of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting enzyme inhibitor: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"NEJM"},{"key":"10.1016\/j.ihj.2013.12.049_bib46","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM199711273372202","article-title":"A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib47","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.CIR.101.11.1297","article-title":"Canadian Implantable Defibrillator Study (CIDS) \u2013 a randomised trial of implantable cardioverter defibrillator against amiodarone","volume":"101","author":"Connoly","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.049_bib48","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/01.CIR.102.7.748","article-title":"Randomised comparison of anti-arrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH)","volume":"102","author":"Kuck","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.049_bib49","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":"Meta analysis of ICD secondary prevention trials \u2013 AVID, CASH & CIDS","volume":"21","author":"Connoly","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2013.12.049_bib50","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.0000012350.99718.AD","article-title":"Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT)","volume":"105","author":"Bansch","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2013.12.049_bib51","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0735-1097(03)00297-3","article-title":"Amiodarone versus implantable cardioverter defibrillator: randomised trial in patients with nonischaemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia\u2013AMIOVIRT","volume":"41","author":"Strickberger","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2013.12.049_bib52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of beta blockers, amiodarone plus beta blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators. The OPTIC study: a randomised trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2013.12.049_bib54","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"GISSI \u2013 Prevenzione Group. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-P trial","volume":"354","author":"Marchioli","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib55","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients: a randomised open label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2013.12.049_bib56","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/2012.jama.11374","article-title":"Association between omega \u2013 3 fatty acid supplementation and risk of major cardiovascular disease events: a systemic review and meta analysis","volume":"308","author":"Rizos","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2013.12.049_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/6.suppl_D.103","article-title":"The idiopathic Long QT syndrome: pathogenetic mechanisms and therapy","volume":"6","author":"Schwartz","year":"1985","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2013.12.049_bib58","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.hrthm.2009.02.009","article-title":"Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, Catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome","volume":"6","author":"Kaufman","year":"2009","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ihj.2013.12.049_bib59","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa0708006","article-title":"Left cardiac sympathetic denervation for CPVT","volume":"358","author":"Wilde","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2013.12.049_bib60","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jacc.2004.02.034","article-title":"Short QT syndrome: pharmacological treatment","volume":"43","author":"Gaita","year":"2004","journal-title":"J Am Coll Cardiol"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321300446X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321300446X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T21:39:39Z","timestamp":1565127579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001948321300446X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":60,"alternative-id":["S001948321300446X"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2013.12.049","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy to reduce arrhythmic mortality","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2013.12.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Cardiological Society of India. Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}